Home News

ROVI and the EIB agreement

ROVI and the EIB agree to sign a loan to boost research into drug administration and prolonged-release technologies

Thu, 21/12/2017 - 18:33 0 min
No votes yet
 
Related
ROVI achieves a 10% increase in operating income and 55% in net profit
ROVI achieves a 10% increase in operating income and 55% in net profit
Laboratorios Farmacéuticos Rovi, SA (BME: ROVI), company Pan-European pharmaceutical company specialized and dedicated to the research,...
5 min
24/02/2021
Full Year 2020 Results Press Release
0 min
24/02/2021
ROVI completes the manufacture of the first batches of Moderna vaccine
0 min
13/01/2021